Sign in

You're signed outSign in or to get full access.

Richard Prins

Chairman of the Board of Directors at IGC PharmaIGC Pharma
Board

About Richard Prins

Richard Prins (age 68) is the independent Chairman of IGC’s Board, serving since May 2007; his current Class B term runs through the 2027 annual meeting . He chairs the Audit and Compensation Committees (since 2012) and also serves as Chair of the Board’s Disclosure Committee; the Board designates him (and fellow member James Moran) as an audit committee financial expert under SEC rules . Prins’ background spans investment banking (Director of Investment Banking at Ferris, Baker Watts, 1996–2008; consulting at RBC until Jan 2009), and he holds a B.A. from Colgate University and an M.B.A. from Oral Roberts University .

Past Roles

OrganizationRoleTenureCommittees/Impact
Ferris, Baker Watts (FBW)Director of Investment BankingMar 1996–2008Led investment banking; capital markets expertise
RBCConsultant2008–Jan 2009Advisory role post-FBW

External Roles

OrganizationRoleTenureCommittees/Impact
Amphastar Pharmaceuticals, Inc.DirectorSince Feb 2003Longstanding public biopharma directorship

Board Governance

  • Independence and structure: The Board (small-cap listing on NYSE American) deems Prins independent; the Board separates the Chair and CEO roles, with Prins as independent Chair .
  • Committee leadership and expertise:
    • Audit Committee: Members Richard Prins (Chair) and James Moran; both designated “audit committee financial experts” .
    • Compensation Committee: Members Richard Prins and James Moran; Prins serves as Chair per company disclosure of his committee chairmanship since 2012 .
    • Disclosure Committee: Prins is the appointed Chair; committee oversees internal controls and public disclosures and meets at least quarterly .
    • Nominating/Governance: Not yet established; company intends to form this committee in the future (current director nominations handled by majority of independent directors) .
  • Attendance and engagement:
    • FY2025 meetings: Board (6), Audit (5), Compensation (2) – all directors and committee members attended all meetings (implies 100% attendance for Prins) .
    • FY2024 meetings: Board (12), Audit (5), Compensation (2), Investment (1) – all attended (implies 100% attendance for Prins) .
Meeting ActivityFY2024 CountFY2024 AttendanceFY2025 CountFY2025 Attendance
Board12All directors attended 6All directors attended
Audit Committee5All members attended 5All members attended
Compensation Committee2All members attended 2All members attended

Additional policies and governance signals:

  • Director stock ownership guidelines require directors to retain 35% of stock received during service (transfers to trusts/gifts excluded) .
  • Hedging prohibitions: Officers and non-employee directors are prohibited from hedging company stock (e.g., swaps, collars) .
  • Indemnification agreements in place for directors .

Fixed Compensation

  • FY2025: “No compensation was awarded to, earned by, or paid to non-employee directors” (i.e., zero director pay in FY2025) .
  • The company states it has a “standard compensation arrangement” for non-employee directors (e.g., fees for committee service, chair roles, meeting attendance), but specific cash retainer/fee amounts were not disclosed in FY2024/FY2025 proxies .

Performance Compensation

Director equity compensation (non-employee directors):

  • FY2024 director compensation table shows equity-only compensation for Prins (927 stock awards; total grant-date fair value $259k) .
  • FY2025: company disclosed no director compensation awards during the fiscal year (i.e., no equity granted) .
  • Award types include performance-based (milestone) and market-price-based stock awards per proxy narrative .
MetricFY2024FY2025
Stock awards granted to Prins (count)927 0 (no director comp awarded)
Total equity grant value to Prins ($)$259,000 $0

Note: Unvested awards at year-end are detailed under Equity Ownership; award categories include performance- and market-price-based grants .

Other Directorships & Interlocks

CompanyIndustryRolePotential Interlock/Conflict
Amphastar Pharmaceuticals, Inc.PharmaceuticalsDirector (since 2003) No related-party transactions between IGC and Prins disclosed; company states no material related-party transactions in last two fiscal years (other than items specifically described) .
  • Related party transactions: Company reports none involving directors in FY2024–FY2025; a March 22, 2024 private placement involved Bradbury Strategic Investment Fund A, not connected to Prins per disclosure .

Expertise & Qualifications

  • Capital markets and finance: Former Director of Investment Banking (FBW), with extensive private equity/investment banking experience; strong knowledge of U.S. capital markets .
  • Audit expertise: Designated “audit committee financial expert” (with James Moran) under SEC rules; significant experience in finance, accounting, and internal controls .
  • Education: B.A. Colgate University; M.B.A. Oral Roberts University .

Equity Ownership

Beneficial ownership and unvested awards:

Ownership MetricJul 1, 2024 (FY2024 reference)Aug 15, 2025 (FY2025 reference)
Beneficially owned shares1,243,000 (1.64%) 1,271,251 (1.40%)
Unvested stock awards (#)1,189 936
Unvested stock awards (value)$653,000 $540,000
  • Stock ownership guideline: Directors must retain 35% of stock received while on the Board .
  • Hedging policy: Directors are prohibited from hedging company stock .
  • Pledging: No pledging disclosures identified in the proxy; not discussed in the cited sections .

Governance Assessment

Key findings:

  • Strengths

    • Independent Chair with deep capital markets experience; separation of Chair/CEO supports oversight .
    • Prins chairs Audit and Compensation Committees and is designated an audit committee financial expert; committees comprised solely of independent directors .
    • Strong engagement: 100% attendance reported for Board and committees in FY2024 and FY2025 .
    • Equity alignment: Material personal stake (1.40% of shares), unvested equity, and retention guideline support alignment with shareholders .
  • Watch items / potential red flags

    • Nominating/Governance Committee not yet established; director nominations handled by independent directors without a formal committee/charter (common for smaller issuers, but below best practice) .
    • Section 16(a) timeliness: late Form 5 filings noted for RSU vesting as of March 31, 2025, including for Richard Prins (administrative compliance lapse) .
    • FY2025 disclosed no director compensation (cash or equity). While not inherently a red flag, it is atypical and may indicate grant timing shifts or compensation deferral; investors should watch for clarity in future filings .
  • Conflicts/related-party

    • Company reports no related-party transactions involving directors in the last two fiscal years; Bradbury private placement involved no disclosed connection to Prins .

Overall implication:

  • Prins’ long-tenured, independent leadership, committee chair roles, and audit expertise are positives for board effectiveness and control oversight. The absence of a formal nominating/governance committee and the late Section 16(a) Form 5 filing are governance gaps to monitor, though not indicative of material conflicts; equity ownership and retention policies support shareholder alignment .